Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Hanna

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 30, 2016
Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approachesDebra Hanna, Klaus Romero, Marco Schito
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development ToolKlaus Romero, Robert Clay, Debra Hanna
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 23, 2016
Tuberculosis eradication versus controlMarco Schito, Debra Hanna, Alimuddin Zumla
Antimicrobial Agents and Chemotherapy|January 30, 2016
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug DevelopmentEric Nuermberger, Christine Sizemore, Klaus Romero, et al.
Nursing Science Quarterly|August 31, 2011
Roy's adaptation model. Interview by Pamela ClarkeStacey H Barone, Debra Hanna, Pamela M Senesac
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2015
Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be DoneMarco Schito, Markus Maeurer, Peter Kim, et al.
The Journal of Infectious Diseases|May 27, 2015
Nonclinical models for antituberculosis drug development: a landscape analysisTawanda Gumbo, Anne J Lenaerts, Debra Hanna, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic OutcomesTawanda Gumbo, Jotam G Pasipanodya, Klaus Romero, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and ConfirmTawanda Gumbo, Jotam G Pasipanodya, Eric Nuermberger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Systematic Analysis of Hollow Fiber Model of Tuberculosis ExperimentsJotam G Pasipanodya, Eric Nuermberger, Klaus Romero, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 30, 2016
Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approachesDebra Hanna, Klaus Romero, Marco Schito
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development ToolKlaus Romero, Robert Clay, Debra Hanna
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 23, 2016
Tuberculosis eradication versus controlMarco Schito, Debra Hanna, Alimuddin Zumla
Antimicrobial Agents and Chemotherapy|January 30, 2016
Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug DevelopmentEric Nuermberger, Christine Sizemore, Klaus Romero, et al.
Nursing Science Quarterly|August 31, 2011
Roy's adaptation model. Interview by Pamela ClarkeStacey H Barone, Debra Hanna, Pamela M Senesac
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2015
Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be DoneMarco Schito, Markus Maeurer, Peter Kim, et al.
The Journal of Infectious Diseases|May 27, 2015
Nonclinical models for antituberculosis drug development: a landscape analysisTawanda Gumbo, Anne J Lenaerts, Debra Hanna, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic OutcomesTawanda Gumbo, Jotam G Pasipanodya, Klaus Romero, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and ConfirmTawanda Gumbo, Jotam G Pasipanodya, Eric Nuermberger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Systematic Analysis of Hollow Fiber Model of Tuberculosis ExperimentsJotam G Pasipanodya, Eric Nuermberger, Klaus Romero, et al.
Pageof 4